Danish/Canadian Spectrum: medical cannabis facility in Odense

Spectrum Cannabis Denmark ApS, a joint venture between Canadian Canopy Growth Corporation, the largest cannabis company in the world, and Danish Cannabis ApS, a leading European hemp producer, has announced plans to establish a 40,000m2 production facility in Odense, Denmark. The immediate conversion of 30,000m2 of existing greenhouse infrastructure could be completed as soon as early 2018, subject to regulatory approvals and licensing, and has the full support of Odense Mayor Peter Rahbæk Juel.
“We are pleased that our efforts to create a stable, skilled and safe environment continues to attract global businesses to Odense, which will now share in the prosperity of the largest and most reputable medical cannabis company in the world,” said Mayor Juel.
Denmark is an ideal country for greenhouse cannabis production because of the abundant availability of experienced greenhouse producers and labourers. Odense was specifically chosen because of the support of the greenhouse industry that exists in the area.
The Odense facility is expected to employ over 125 staff, including its former orchid growers who will all be offered employment with the Company. Based on current usage rates in Canadian patient groups, production capacity from the state-of-the art greenhouse could serve the needs of approximately 60,000 patients, with a retail production value of over 500M DKK.
While the Company proceeds through the Lægemiddelstyrelsen licensing process for production, it expects to import Spectrum Cannabis products from Canada, which are currently sold to medical patients in Canada and Germany.
The Spectrum Cannabis products are based on the simple doctor and patient friendly Spectrum system, which classifies products from high THC to balanced THC and CBD products to high CBD-only products. Throughout 2018, the Company intends to introduce its range of products in dried form for inhalation, as well as cannabis oils and Softgel capsules, an offering currently only available through Canopy Growth’s subsidiaries, Spectrum Cannabis and Tweed.
“The Danish market is a stable, attractive market for a number of strategic reasons,” said Bruce Linton, Chairman and CEO of Canopy Growth. “In Denmark, we see a strong pharmaceutical industry with an equally strong research tradition as well as a skilled labour pool and attractive energy rates. Based on these foundational aspects and with the expertise of our partners at Danish Cannabis, I am confident we will build upon our global success here in Denmark.”
The confidence and trust in the medical control system exercised by Lægemiddelstyrelsen and the evolving cannabis laws in Denmark have created a market opportunity that will create jobs for the community of Odense while also improving the health and quality of lives of Danish people suffering from chronic illnesses by providing a safe and consistent supply of high quality medical cannabis products.
Subject to regulatory approvals, a variety of Spectrum Cannabis products will be available throughout 2018, including over ten dried cannabis strains, and ingestible cannabis oils available in liquid and Softgel capsule formats.